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Prostate cancer survivors approach 2.8 million in number and represent 1 in 5 of all cancer survivors in the United States. While
guidelines exist for timely treatment and surveillance for recurrent disease, there is limited availability of guidelines that facilitate the
provision of posttreatment clinical follow-up care to address the myriad of long-term and late effects that survivors may face. Based
on recommendations set forth by a National Cancer Survivorship Resource Center expert panel, the American Cancer Society devel-
oped clinical follow-up care guidelines to facilitate the provision of posttreatment care by primary care clinicians. These guidelines
were developed using a combined approach of evidence synthesis and expert consensus. Existing guidelines for health promotion,
surveillance, and screening for second primary cancers were referenced when available. To promote comprehensive follow-up care
and optimal health and quality of life for the posttreatment survivor, the guidelines address health promotion, surveillance for prostate
cancer recurrence, screening for second primary cancers, long-term and late effects assessment and management, psychosocial
issues, and care coordination among the oncology team, primary care clinicians, and nononcology specialists. A key challenge to the
development of these guidelines was the limited availability of published evidence for management of prostate cancer survivors after
treatment. Much of the evidence relies on studies with small sample sizes and retrospective analyses of facility-specific and
population databases. CACancer J Clin 2014;64:225-249.VC 2014 American Cancer Society.
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Introduction
Prostate cancer survivors approach 2.8 million in number and represent 1 in 5 of all cancer survivors and over 4 in 10 male
cancer survivors in the United States.1 Given that long-term survival is common after prostate cancer treatment, distinctly
characterizing cancer survivorship (the phase of care after active treatment) and addressing survivors’ unique needs are criti-
cal to quality cancer care.2 Nearly a decade ago, a landmark report from the Institute of Medicine entitled From Cancer
Patient to Cancer Survivor: Lost in Transition highlighted the unique issues facing all cancer survivors as well as the growing
need for guidance with respect to quality survivorship care.3 With nearly 14 million cancer survivors,1 this report is relevant
to these survivors, their caregivers and advocates, primary and specialty care clinicians, insurers, employers, funding agencies,
and policy makers. In recognition of the increasing need for information resources to support primary care clinicians who
care for prostate cancer survivors, these guidelines were developed in response to the National Cancer Survivorship Resource
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Center (The Survivorship Center [cancer.org/survivorship-
center]) strategic recommendations aimed at enhancing the
quality of clinical follow-up care for cancer survivors who
have completed initial treatment (eg, surgery, radiation,
and/or chemotherapy) and are transitioning back to the
routine care typically provided by a primary care clinician.4
The Survivorship Center is a collaboration between the
American Cancer Society (ACS) and The George Wash-
ington University Cancer Institute funded through a
5-year cooperative agreement with the Centers for Disease
Control and Prevention. The Survivorship Center aims to
impact individual, systems, and policy gaps in posttreat-
ment survivorship clinical care and resources to help
survivors achieve optimal health and quality of life (QOL)
and increase the importance of posttreatment survivorship
as a public health issue.4
BACKGROUND
Each year, approximately 240,000 men in the United States
are diagnosed with prostate cancer and begin their journey
into prostate cancer survivorship.1 Most prostate cancers are
diagnosed by prostate-specific antigen (PSA) testing.1,5-7
The median age at diagnosis is 67 years and over 90% of men
are diagnosed with local or regional disease, for which the 5-
year relative survival rate approaches 100%.1 Over the past 25
years, the 5-year relative survival rate (compared with similar
individuals without cancer) for all stages combined has
increased from 68.3% to 99.9%. The 10-year and 15-year rel-
ative survival rates are 97.8% and 91.4%, respectively.1 These
trends in survival have been attributed to a combination of
early detection,2 increasingly effective treatment of localized
and advanced disease,8 lead-time bias (early diagnosis falsely
appears to prolong survival), and overdiagnosis (often due to
the widespread use of PSA screening).9 However, trends in
survival and QOL outcomes continue to vary across socioeco-
nomic, racial, and ethnic boundaries. Prostate cancer survi-
vors with lower income and less education and from
nonwhite populations tend to have poorer QOL and a lower
likelihood of survival compared with higher-income, more
educated, and white prostate cancer survivors.10-12
The treatment of prostate cancer varies based on risk of
disease progression, comorbidity, and patient and clinician
preferences due, in part, to its preference-sensitive
nature.13-15 The type of treatment provided may also be
impacted by age, race, ethnicity, access to oncology services,
and socioeconomic status.16-18 As illustrated in Figure 1,1
initial treatment patterns indicate that 57% of men aged
younger than 65 years are treated with radical prostatec-
tomy and 25% receive radiation therapy.1 Among those
aged 65 to 74 years, 42% undergo radiation therapy and
33% undergo radical prostatectomy.1 Based on disease
severity, some patients may undergo combination treatment
with radical prostatectomy followed by radiation therapy or
androgen deprivation therapy (ADT) coupled with radia-
tion therapy. Observational data indicate African American
men diagnosed with localized/regional prostate cancer are
more likely to undergo radiation therapy than surgery.
They are also diagnosed with prostate cancer at younger
ages and present with more advanced disease.19,20 The lat-
ter is true among both insured and uninsured patients.10
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Prostate cancer survivors often have comorbid health condi-
tions. For those diagnosed with localized disease between
1999 and 2005, between 2% and 14% died of their cancer
depending on their age and comorbidities.21 The vast majority
died of other causes. Expectant management approaches,
which include active surveillance (monitoring the cancer
closely with PSA, digital rectal examination [DRE], and
ultrasound-guided prostate biopsy at regular intervals to deter-
mine whether the cancer is growing) and watchful waiting
(less intensive follow-up with fewer tests and monitoring the
man’s symptoms to decide whether treatment is needed),22
are therefore increasingly used for patients with less aggressive
disease biology and/or a shorter life expectancy to avoid or
delay treatment and its potential side effects.23 However, use
of these approaches remains relatively uncommon (approxi-
mately 34% of patients) despite concerns about prostate cancer
overdiagnosis and subsequent overtreatment.9,24
Research addressing prostate cancer survivorship is emerg-
ing, yet remains sparse despite growing recognition of the
long-term implications of a prostate cancer diagnosis.25 For
example, a literature review published in 2011 indicated that
fewer than 10 prostate cancer survivorship studies are pub-
lished each year.25 Many prostate cancer survivors experience
long-term and late effects of the disease and its treatment,
including urinary incontinence, sexual dysfunction, bowel
issues, and adverse psychosocial and relationship effects
(Table 1).26-30 In addition, practical issues, such as employ-
ment, insurance, and finances, may have all been impacted by
cancer treatment.31 Furthermore, these long-term and late
effects are often exacerbated by existing comorbidities.32
Accordingly, treatment-related regret (feelings of loss or dis-
tress over a decision made under uncertain conditions) may
occur in as much as 20% of patients.33,34 Treatment-related
regret may be influenced by the presence of adverse effects
such as urinary and sexual functioning, and be more common
after surgery among African American patients.33,35
Differential treatment outcomes tend to adversely impact
African American prostate cancer survivors with respect to
cancer control and general, urinary, and sexual health-related
QOL (HRQOL); however, the reasons for these disparities
are not completely understood.36-38 There is also insufficient
information regarding outcomes for Hispanic, Native Amer-
ican, Asian, rural, and homosexual men diagnosed with
prostate cancer as most published information on treatment
outcomes, particularly for HRQOL, is based on the experi-
ence of well-educated, married, heterosexual, white men.12
Further research is needed into how best to care for prostate
cancer survivors from different racial and ethnic minority
populations as well as men who have sex with men.38,39
Despite the growing need, no known comprehensive
guidelines exist to direct the care of men surviving prostate
cancer. The National Comprehensive Cancer Network
(NCCN) has guidelines that address prostate cancer treat-
ment and surveillance for recurrent disease40 as well as general
survivorship guidelines41 for managing certain late effects (eg,
anxiety, fatigue) that affect some prostate cancer survivors.
FIGURE 1. Prostate Cancer Primary Treatment Patterns by Age, 2008. Bar graph is shown illustrating initial prostate cancer treatment patterns percen-
tages by age range. Reproduced with permission from Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Can-
cer J Clin. 2012;62:220-241.1
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However, further efforts are needed to build upon existing
resources, particularly with regard to guidance and support
for primary care clinicians. Physician and nonphysician pri-
mary care clinicians often rely on prostate cancer specialists
(urologists and radiation and medical oncologists) to help
them manage the care of cancer survivors. Survivors them-
selves may rely on cancer specialists for cancer-related and
non–cancer-related care.42,43 However, scant information
TABLE 1. Summary of Common Long-Term and Late Effects of Prostate Cancer and Its Treatment
TREATMENT TYPE LONG-TERM EFFECTS LATE EFFECTS
Surgery
(radical prostatectomy:
open, laparoscopic,
robotic-assisted)
Urinary dysfunction
l Urinary incontinence (stress)
l Urinary symptoms (urgency, frequency, nocturia, dribbling)
l Urethral stricture formation (scarring at the urethra)
Sexual dysfunction
l ED
l Lack of ejaculation
l Orgasm changes (without erection, associated with incontinence)
l Penile shortening
Disease progression
Radiation
(external beam or
brachytherapy)
Urinary dysfunction
l Urinary incontinence
l Urinary symptoms (dysuria, urgency, frequency, nocturia, dribbling)
l Hematuria
l Urethral stricture
Sexual dysfunction
l Progressive ED
l Decreased semen volume
Bowel dysfunction
l Fecal urgency, frequency, incontinence
l Blood in stool
l Rectal inflammation, pain
Urinary dysfunction
l Urethral stricture
l Hematuria due to small blood vessel changes
Sexual dysfunction
l ED can be delayed in onset 6 to 36 mo after therapy
Bowel dysfunction
l Rectal bleeding secondary to thinning/small blood
vessel changes of anterior rectal wall mucosa
l Disease progression
Hormone
(androgen deprivation
therapy)
Sexual dysfunction
l Loss of libido
l ED
Other
l Hot flushes/sweats
l Weight gain, abdominal obesity
l Change in body image
l Excessive emotional reactions and frequent mood changes
l Depression
l Fatigue/decreased activity
l Gynecomastia
l Anemia
l Body hair loss
l Dry eyes
l Osteoporosis, fractures
l Metabolic syndrome
l Cardiovascular disease (possible increased risk of
myocardial infarction)
l Diabetes; decreased sensitivity to insulin and oral
glycemic agents
l Increased cholesterol
l Increased fat mass and decreased lean muscle
mass/muscle wasting
l Venous thromboembolism
l Vertigo
l Cognitive dysfunction
l Disease progression
Expectant management
(active surveillance or
watchful waiting)a
l Stress, anxiety, worry
l Risks associated with repeat biopsy (active surveillance),
PSAs and DREs
l Symptoms associated with disease progression
l Disease progression
GENERAL PSYCHOSOCIAL LONG-TERM AND LATE EFFECTS
l Depression, depressive symptoms
l Distress (multifactorial unpleasant experience of psychological, social, and/or spiritual nature)
l Worry, anxiety
l Fear of recurrence
l Pain-related concerns
l End-of-life concerns: death and dying
l Changes in sexual function and/or desire
l Challenges with body image (secondary to surgery, hormonal therapy)
l Challenges with self-image
l Relationship and other social role difficulties
l Return to work concerns and financial challenges
ED indicates erectile dysfunction; PSA, prostate-specific antigen; DRE, digital rectal examination. aAccording to the National Cancer Institute Dictionary of Can-
cer Terms, active surveillance indicates a treatment plan that involves closely watching a patient’s condition but not giving treatment unless there are changes
in test results that show the condition is getting worse. Active surveillance may be used to avoid or delay the need for treatments such as radiation therapy
or surgery, which can cause side effects or other problems. During active surveillance, certain exams and tests are done on a regular schedule. It may be
used in the treatment of certain types of cancer, such as prostate cancer. It is a type of expectant management. Watchful waiting indicates closely watching
a patient’s condition but not giving treatment unless symptoms appear or change. Watchful waiting is sometimes used in conditions that progress slowly. It is
also used when the risks of treatment are greater than the possible benefits. During watchful waiting, patients may be given certain tests and exams. Watchful
waiting is sometimes used in prostate cancer. It is a type of expectant management.
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is available regarding the degree to which cancer specialists
are meeting the increasing needs of cancer survivors and
their primary care clinicians.44-46 Due to the prolonged
natural history of prostate cancer and the growing number
of survivors, primary care clinicians inevitably participate in
the care of these men.47 Yet it is often unclear who has
principal responsibility for prostate cancer survivorship care
and what it entails.42,44
For these reasons, The Survivorship Center4 convened a
multidisciplinary expert workgroup to review the current lit-
erature on prostate cancer, its treatments, and their effects
in order to provide clinical follow-up care guidelines focused
on the role of primary care clinicians in caring for prostate
cancer survivors. The survivorship topic areas examined
include health promotion (nutrition, physical activity,
smoking cessation, alcohol consumption), surveillance for
cancer recurrence and screening for second primary cancers,
physical and psychosocial long-term and late effects, and
care coordination and practice implications. The resulting
ACS Prostate Cancer Survivorship Care Guidelines provide
a combination of evidence and expert clinical practice-based
management recommendations to guide prostate cancer sur-
vivorship care in primary care settings.
METHODS
Literature Review
To develop the ACS Prostate Cancer Survivorship Care
Guidelines, The Survivorship Center conducted multiple
literature searches. An initial search, conducted in the fall of
2012, was used to establish a foundation of published evi-
dence for use with an expert workgroup composed of 16
multidisciplinary experts specializing in the care of patients
with prostate cancer and the treatment of long-term and
late effects experienced by prostate cancer survivors. Experts
were nominated by The Survivorship Center’s Steering
Committee and ACS staff and were selected to represent
both primary care and oncology perspectives, with a specific
focus and expertise in prostate cancer treatment and follow-
up care. The Survivorship Center selection process estab-
lished 20 members as the workgroup maximum to ensure
feasibility of discussions and division of work. Topic areas
for the initial literature search included health promotion
(nutrition, physical activity, tobacco/smoking cessation, and
avoiding/limiting alcohol consumption), surveillance for
cancer recurrence and screening for second primary cancers,
physical and psychosocial long-term and late effects, and
care coordination. Using PubMed and the inclusion criteria
defined below, Survivorship Center staff selected key articles
published between 2004, after the publication of the
National Action Plan for Cancer Survivorship,48 and 2012,
when the guidelines development began. Search terms were
based on treatment types and the specific long-term or late
effects of interest. Search terms included: cancer survi-
vor1 review or meta-analysis or systematic review1 guide-
lines or guidance paired with prostate cancer, prostate
cancer survivor, or prostate cancer patient posttreat-
ment1 (symptom management, late effects, long-term
effects, psychosocial care, palliative care, health promotion,
surveillance, screening for new cancers, self-management,
guidelines or guidance, follow up or follow-up, side
effects1 chemotherapy, side effects1 radiation, side
effects1 surgery, treatment complications, genetic counsel-
ing and testing, survivor or patient interventions, provider
interventions, provider education, barriers). To gain a better
understanding of the components that could be included in
comprehensive survivorship care guidelines, staff reviewed
the Long-Term Follow-Up Guidelines for Survivors of
Childhood, Adolescent, and Young Adult Cancers of the
Children’s Oncology Group (survivorshipguidelines.org). In
addition, staff researched other domestic and international
guidelines published to guide clinical follow-up care of cancer
survivors to ensure that ACS guidelines were not duplicative
of existing information. Staff leveraged the expertise of the
ACS librarian and Survivorship Center principal investigator
to conduct the literature search and determine inclusion/
exclusion criteria for publications. An independent systematic
evidence review was not conducted.
In November 2012, the expert workgroup convened and
was tasked with reviewing the list of publications and adding
any additional relevant publications. Inclusion criteria for
additional publications included criterion a and any one of the
following (b-d): a) peer-reviewed publication in English since
2004; b) seminal article(s) prior to this date that continue to
strongly influence clinical practice, including randomized
controlled trials (RCTs), prospective studies, and well-
conducted population-based case-control studies; c) large
studies with more than 200 cancer cases analyzed; and/or
d) high-quality assessment of covariates and analytic methods
(analyses controlled for important confounders [eg, preexist-
ing comorbid conditions]). Additional publications that were
identified included guidelines or guidance developed by other
organizations (eg, NCCN,40,41,49 Michigan Cancer Consor-
tium50), specific medical centers (eg, The University of Texas
MD Anderson Cancer Center Clinical Tools and Resources
Prostate Cancer Survivorship algorithm51), or available from
other countries (eg, Australia Cancer Survivorship Centre).
Studies on childhood cancers, qualitative studies, and non-
English publications were excluded. A total of 468 articles
(see online supporting information) met the inclusion criteria
for the literature review and 222 were included as citations to
support the guidelines. The majority of the citations support-
ing long-term and late effect description and management
recommendations rely largely on case-control studies with
fewer than 500 participants and reviews that combine studies
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with varying outcome measures. There were several studies
that used existing population-based data to better understand
the impact of treatment on long-term and late effects. There
was limited availability of RCTs of prostate cancer survivors.
This lack of clinical trials is a limitation of the current state
of the science for survivorship.
Literature Synthesis and Expert Workgroup
Recommendations
Expert workgroup members were divided among specific
topic-based subgroups based on their preference and asked
to review and synthesize information from publications
related to the specific topic(s). Based on a combination of
published evidence and practice-based experience, each
expert workgroup member drafted clinical follow-up care
recommendations to be considered for inclusion in the
guidelines. Workgroup members were asked to consider
the following criteria as they synthesized their findings:
1. Level of evidence (I, meta-analyses of RCTs; IA, RCT
of prostate cancer survivors; IB, RCT based on cancer
survivors across multiple sites; IC, RCT not based on
cancer survivors but on general population experiencing
a specific long-term or late effect [eg, managing urinary
incontinence, erectile dysfunction, etc]; IIA, non-RCT
based on prostate cancer survivors; IIB, non-RCT based
on cancer survivors across multiple sites; IIC, non-RCT
not based on cancer survivors but on general population
experiencing a specific long-term or late effect [eg,
managing urinary incontinence, erectile dysfunction,
etc]; III, case study; and 0, expert opinion, observation,
clinical practice, literature review, or pilot study).
2. Consistency across studies, including across study
designs (separating results by study design when pre-
senting the evidence).
3. Dose response when presenting long-term and late
effects resulting from radiation therapy.
4. Race/ethnicity differences in diagnosis and treatment that
may impact long-term and late effects of survivorship.
5. Second primary cancers for which survivors are at high
risk due to treatment, genetic considerations, etc.
Draft recommendations were compiled and reviewed by
the entire expert workgroup during 3 conference telephone
calls to develop consensus on the full set of clinical follow-
up care guidelines. In cases of disagreement regarding the
recommendations, workgroup members were asked to
again consider the evidence and achieve consensus for mul-
tidisciplinary clinical practice recommendations.
Upon completion, the guidelines underwent internal
medical review and received approval by the ACS’s National
Board of Directors. During article development, an addi-
tional literature review was conducted to identify articles
published between November 2012 and February 2014 to
ensure the evidence base was up-to-date. While new articles
were added to the literature review, there was no resulting
impact or change in the guidelines. In March 2014, the
guidelines article was sent to internal and external experts for
final review and comment, prior to submission for publica-
tion. This peer-review process primarily resulted in modifi-
cations pertaining to the methods, levels of evidence, and
clarity of the article. While developing survivorship clinical
follow-up care guidelines is a unique and evolving process,
staff sought to align as closely as possible with the estab-
lished ACS process for developing screening guidelines
(Table 2).52 According to the ACS process, these guidelines
will be briefly updated as needed and rewritten every 5 years.
Earlier updates may be initiated should strong evidence be
identified warranting review.
GUIDELINES FOR THE PRIMARY CARE
MANAGEMENT OF PROSTATE CANCER
SURVIVORS HEALTH PROMOTION
Table 3 outlines the nutrition, physical activity, smoking
cessation, and alcohol consumption guidelines for prostate
cancer survivorship. When appropriate, these guidelines
incorporate existing ACS nutrition and physical activity
guidelines for cancer survivors.53
Information
Prostate cancer survivors often report the lack of accessible
quality information to assist with decision-making and
symptom management across the cancer continuum.26,54,55
Study findings suggest unmet information and supportive
care needs are prevalent among prostate cancer survi-
vors.26,55 Because information needs evolve as patients
transition from treatment through various phases of survi-
vorship, survivor and caregiver information needs should
be routinely assessed and met via standard information
about prostate cancer and treatment, long-term and late
effects, and other relevant comorbid health concerns such
as diabetes or cardiovascular disease, with support services
provided as necessary.56
Primary care clinicians should provide regular evaluations
of survivors to determine appropriate levels of participation
in health promotion and lifestyle modification programs.57
Facilitators (eg, clinician and spousal involvement) and bar-
riers to engaging in physical activity (eg, preexisting comor-
bidities) should be addressed and monitored prior to the
initiation of behavior change programs.
Obesity
Obesity has been found to be associated with worse health
outcomes (prostate cancer-specific mortality and biochemi-
cal recurrence) for patients with prostate cancer.58-62 Pri-
mary care clinicians should conduct routine assessments of
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body mass index among survivors across the prostate cancer
survivorship continuum. For survivors who are overweight
or obese, clinicians should recommend limiting the con-
sumption of high-calorie foods and beverages and promote
weight loss activities such as increasing physical activity53,57
as they would do for patients without cancer.
Physical Activity
Some cohort studies have suggested that physical activity
may decrease the risk of prostate cancer recurrence, improve
cancer-specific and overall survival, hasten recovery from
the immediate side effects of treatment, and prevent long-
term effects.53,63-65 Various intervention studies among
cancer survivors show that exercise can improve fatigue,
anxiety, depressive symptom management, self-esteem,
happiness, and QOL.66 Primary care clinicians should edu-
cate survivors regarding the association between physical
activity and lower overall and prostate cancer-specific mor-
tality and improved HRQOL. Although the evidence relat-
ing these recommendations to prostate cancer recurrence
has limitations, survivors should be informed that there are
other substantial benefits, such as decreasing the risk of car-
diovascular disease and improved physical functioning.67
Primary care clinicians should counsel survivors to avoid
inactivity and assist with ensuring a return to normal
daily activities as soon as possible after diagnosis.
TABLE 2. Comparison of ACS Survivorship Care Guideline Development Process With ACS Cancer Screening
Guideline Development Process
STANDARDS
ACS PROCESS FOR CANCER SCREENING
GUIDELINE DEVELOPMENT
ACS SURVIVORSHIP CARE GUIDELINE
DEVELOPMENT PROCESS
Transparency A published article defines the new ACS process, and all
ongoing and planned work in cancer screening guideline
production and revision will be posted on the
ACS Web site.
An article was published describing the survivorship
care guideline process and the details are outlined in
the methodology of each guideline article.
Conflicts of interest ACS guideline developers will publicly declare financial
and institutional conflicts, and all will be expert generalists
to avoid the appearance of professional conflicts.
ACS survivorship care guideline developers will publicly
declare financial and institutional conflicts. The
guidelines panels will represent a diverse group of
providers, including oncologists, surgeons, primary
care clinicians, psychosocial providers, etc. to avoid
the appearance of professional conflicts.
Group composition Guidelines will be developed by a 12-person panel of
multidisciplinary experts in clinical screening, including
a patient advocate.
Survivorship care guideline expert panels will consist of
10-15 practicing oncology experts. At least one
member of each panel will represent the primary
care field.
Systematic review of evidence The ACS will commission high-quality and independent
systematic evidence reviews to serve as the basis for
all guidelines.
The ACS will conduct preliminary systematic evidence
reviews to develop a foundation for expert panelists.
Expert panelists will divide into topic-focused
subgroups and conduct additional literature review
and analysis to serve as the basis for all guidelines.
When applicable, existing guidelines for health
promotion, screening, surveillance, and psychosocial
care will be incorporated.
Grading strength of recommendations The ACS will be explicit about harms as well as
benefits, and will develop a grading scheme to rate
confidence in recommendations that will be consistent
with methods used by other organizations.
The ACS developed a consistent grading scheme that
is outlined in the methodology section of each
survivorship care guideline. This grading scheme is
consistent with methods used by other organizations
endeavoring to develop survivorship care guidelines.
Articulation of recommendations ACS guidelines will be written for audiences of
primary care clinicians, the general public, and policy
makers.
ACS survivorship care guidelines are written for primary
care clinicians. Resources will be developed to
support the information needs of the general public
and policy makers.
External review Before publication, all draft guidelines will be vetted
by relevant experts, organizations, and societies, and
any differences will be explicitly discussed in the
published guideline.
Before publication, all draft survivorship care guidelines
will be vetted by internal experts, the Priority Mission
Outcomes Committee, National Board of Directors,
and relevant external experts, organizations, and
societies. Any differences will be explicitly discussed
in the published guideline.
Updating ACS guidelines will be briefly updated as needed,
and at a minimum at least annually online with
relevant new studies, and rewritten every 5 y.
ACS survivorship care guidelines will be briefly updated as
needed, and at a minimum at least annually online
with relevant new studies, and rewritten every 5 y.
ACS indicates American Cancer Society.
American Cancer Society Prostate Cancer Survivorship Guidelines
232 CA: A Cancer Journal for Clinicians
Survivors without physical limitations or contraindications
should aim for at least 150 minutes per week of moderate-
intensity exercise or 75 minutes per week of vigorous-
intensity aerobic physical activity, or an equivalent combi-
nation of moderate and vigorous intensity aerobic physical
activity, which may include routine weight-bearing exer-
cises.53 Research has demonstrated that 3 or more hours
per week of vigorous activity among prostate cancer survi-
vors was associated with a 61% reduction in prostate
cancer-specific death and a nearly 50% reduction in all-
cause mortality.53,64
Nutrition
Although research is ongoing, findings suggest that dietary pat-
terns high in vegetables, fruits, and whole grains improve sur-
vival and decrease the risk of second cancers and chronic
diseases among cancer survivors.53,68 The ACS guidelines for
nutrition and physical activity for cancer survivors recommend
that diets for prostate cancer survivors should emphasize
micronutrient-rich and phytochemical-rich vegetables and
fruits, low amounts of saturated fat, an intake of at least 600 IU
of vitamin D per day, and consuming adequate, but not exces-
sive, amounts of dietary sources of calcium (ie, not to exceed
1200 mg/day).53 These dietary suggestions are especially rele-
vant to survivors receiving ADT due to their increased risk of
osteoporosis and fractures. Survivors with nutrition-related
challenges, such as bowel problems affecting nutrient absorp-
tion, should be referred to a registered dietitian, preferably one
who is also a Certified Specialist in Oncology Nutrition if
available, for specialized nutrition counseling. Survivors should
also be instructed to avoid or limit alcohol consumption to no
more than 2 drinks per day as per the ACS guidelines.53
Smoking Cessation
Smoking after treatment of prostate cancer increases the
risk of cancer recurrence and second cancers.69,70 Primary
care clinicians should assess for tobacco use and offer and/
or refer survivors to cessation counseling and resources.57
Clinical guidelines are available from the Agency for
Healthcare Research and Quality’s Guide to Clinical Pre-
ventive Services (ahrq.gov/professionals/clinicians-providers/
guidelines-recommendations/tobacco/clinicians/update/
treating_tobacco_use08.pdf).71
SURVEILLANCE FOR PROSTATE CANCER
RECURRENCE
The literature is not definitive with regard to how often
PSA levels should be monitored to detect prostate cancer
recurrence after treatment or how best to follow men on
active surveillance.72,73 The NCCN guidelines for prostate
cancer treatment40 recommend measuring serum PSA lev-
els every 6 to 12 months for the first 5 years after definitive
treatment and then to recheck annually. This recommen-
dation is routinely updated and is reflected as a component
of the surveillance guidelines in Table 4. Because the
recurrence of prostate cancer may result in substantial mor-
bidity and can in rare cases occur in the absence of a
PSA elevation, an annual DRE is also appropriate to
monitor for prostate cancer recurrence after treatment.40
TABLE 3. Health Promotion Guidelines
GUIDELINE LEVEL OF EVIDENCEa
Assess information needs related to prostate cancer and its treatment, side effects, other health concerns, and available support
services and provide or refer survivors to appropriate resources to meet these needs.
0
Counsel survivors to achieve and maintain a healthy weight by limiting consumption of high-calorie foods and beverages
and promoting increased physical activity.
III, 0
Counsel survivors to engage in at least 150 min per wk of physical activity, this may include weight-bearing exercises. III, 0
Counsel survivors to achieve a dietary pattern that is high in fruits and vegetables and whole grains.
l Consume a diet emphasizing micronutrient-rich and phytochemical-rich vegetables and fruits, low amounts of saturated fat,
intake of at least 600 IU of vitamin D per d and consuming adequate, but not excessive, amounts of dietary sources of
calcium (not to exceed 1200 mg/d).
l Refer survivors with nutrition-related challenges (eg, bowel problems that impact nutrient absorption) to a registered dietitian.
III, 0
Counsel survivors to avoid or limit alcohol consumption to no more than 2 drinks per d. III, 0
Assess for tobacco use and offer and/or refer survivors to cessation counseling and resources.
Counsel survivors to avoid tobacco products.
III, 0
IU indicates international units. aLevel of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of prostate cancer survivors; IB, RCT based
on cancer survivors across multiple sites; IC, RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (eg,
managing urinary incontinence, erectile dysfunction, etc); IIA, non-RCT based on prostate cancer survivors; IIB, non-RCT based on cancer survivors across mul-
tiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (eg, managing urinary inconti-
nence, erectile dysfunction, etc); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study.
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Prostate cancer surveillance with PSA and DRE is recom-
mended to remain under the purview of the primary treating
specialist until an explicit transfer of responsibility to the pri-
mary care clinician is initiated. Primary care clinicians are
often involved with prostate cancer treatment decision-
making and may already be involved in the care of men dur-
ing and after treatment.74,75 However, once the migration or
explicit transfer of responsibility for cancer surveillance to
the primary care clinician has occurred, the following recom-
mendations can guide PSA testing intervals and thresholds
for referral according to initial treatment type.
After radical prostatectomy, the PSA usually drops to an
undetectable level (less than 0.03 ng/mL) within a 2-month
period. There is more than one definition of postradical pros-
tatectomy biochemical recurrence.76,77 Therefore, any con-
firmed detectable PSA level after surgery is an indication for
referral to the primary treating specialist. After radiation ther-
apy, the PSA falls slowly and reaches its lowest level (“PSA
nadir”) after 6 months to several years; the target PSA is less
than 1.0 ng/mL. Referral should be made for a rising PSA
trend after the nadir is reached even when the absolute values
are low.78 A “PSA bounce” may occur, usually within 2 years,
in which the PSA level begins to rise and then comes back
down.79-81 In contrast to prostate cancer recurrence, this phe-
nomenon is self-limited, although it may still raise concerns
for patients and primary care clinicians.78 A DRE and con-
sultation with the primary treating radiation therapist is rec-
ommended after confirmation of a rising PSA in 3 months.
Among men treated with ADT, each has a different rate
of PSA decline and nadir. The overarching goal should be
to achieve a PSA level less than 0.05 or 0.1 ng/dL depend-
ing on the assay.78 The decline should be within 6 to 8
weeks but will depend on the PSA level at the time of ADT
initiation (ie, higher PSA levels take longer to decline).
Achieving a low PSA level after the initiation of ADT has
prognostic value. For example, in patients with metastatic
disease, achievement of a PSA nadir of 4 ng/mL or less after
7 months of ADT is a strong predictor of survival.82,83
ADT is generally managed by the primary treating specialist
throughout its duration. However, as will be discussed
below, the primary care clinician may need to be involved in
monitoring and managing the adverse effects of ADT
(eg, metabolic syndrome).
SCREENING FOR SECOND PRIMARY CANCERS
Clinicians should be aware of a small increased risk of sec-
ondary malignancies after radiation therapy compared with
men receiving surgery.84-86 Several large-scale studies of
irradiated patients have indicated a slightly increased risk of
secondary neoplasms in the irradiated area in both the
bladder and colon/rectum.87-89 Evidence does not support
increased frequency or intensity of screening, but adherence
to routine ACS screening guidelines for the early detection
of any new cancers is recommended (Table 5). Time is
needed to determine whether advanced techniques to
deliver higher more focal radiation doses will impact rates
of bladder or bowel cancer.
It is recommended that prostate cancer survivors presenting
with hematuria should undergo a thorough evaluation to rule
out bladder cancer; however, screening asymptomatic prostate
cancer survivors with urinalysis is not recommended. For
patients with rectal cancer, keeping up-to-date with colorectal
cancer screening for all age-appropriate/risk-appropriate men
and a thorough evaluation of new rectal bleeding (even if
colorectal cancer screening is current) is recommended. Persis-
tent bleeding, pain, or other symptoms of undetermined ori-
gin may require multidisciplinary management including
evaluation by an appropriate specialist for diagnostic evalua-
tion as well as the treating radiation oncologist.
ASSESSMENT AND MANAGEMENT OF
PHYSICAL AND PSYCHOSOCIAL EFFECTS OF
PROSTATE CANCER AND TREATMENT
Survivors should be assessed for physical (eg, urinary, sexual,
bowel) and psychosocial effects of prostate cancer and its
TABLE 4. Surveillance Guidelines for Prostate Cancer Recurrence
GUIDELINE LEVEL OF EVIDENCEa
Measure serum PSA level every 6 to 12 mo for the first 5 y, then recheck annually thereafter. 2Ab
Refer survivors with elevated or rising PSA level back to the primary treating specialist for further follow-up and treatment. 0
Perform an annual DRE in coordination with cancer specialist to avoid duplication. 2Ab
PSA indicates prostate-specific antigen; DRE, digital rectal examination. aLevel of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of
prostate cancer survivors; IB, RCT based on cancer survivors across multiple sites; IC, RCT not based on cancer survivors but on general population experienc-
ing a specific long-term or late effect (eg, managing urinary incontinence, erectile dysfunction, etc); IIA, non-RCT based on prostate cancer survivors; IIB, non-
RCT based on cancer survivors across multiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term
or late effect (eg, managing urinary incontinence, erectile dysfunction, etc); III, case study; 0, expert opinion, observation, clinical practice, literature review, or
pilot study. bNational Comprehensive Cancer Network rating indicates that “based upon lower-level evidence, there is uniform consensus that the intervention is
appropriate.”
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treatment; the focus of assessment should be tailored to the
type of cancer treatment received and current disease state to
trigger appropriate self-management and clinical management
strategies for support and therapy. Assessing baseline patient-
reported HRQOL and tracking HRQOL at least annually is
an important element of high-quality survivorship care.38,90
Validated surveys such as the 5-item Sexual Health Inven-
tory for Men survey (Fig. 2)91-93 or the International Index
of Erectile Function94 or more comprehensive measures of
prostate cancer HRQOL such as the Expanded Prostate
Cancer Index Composite for Clinical Practice (EPIC-
CP)95,96 are helpful in identifying and understanding the
side effect burden. If brief screening tools are not available,
simply starting a conversation around urinary and sexual
function may uncover symptom burdens. Shared decision-
making around patient-reported problem areas may help
inform clinical management decisions including whether to
pursue referral and recommendations for follow-up.
The following physical and psychosocial effects may be
experienced by prostate cancer survivors. Varying levels of
evidence exist to demonstrate the presence of these effects
during survivorship. There is often limited information on
the time interval after treatment as well as the prevalence of
these effects among survivors. The guidelines (Table 6)
combine available evidence with expert consensus to assist
primary care clinicians in managing prostate cancer survi-
vorship care.
Anemia
Anemia is a common complication of ADT.97,98 The well-
known effect of androgens on erythropoiesis leads to the
side effect of a normochromic normocytic anemia in men
undergoing ADT.98 Periodic monitoring (eg, annual) of
complete blood counts should be considered and anemia
evaluated with a focus on potential causes other than ADT.
There are no convincing data to support the routine treat-
ment of asymptomatic anemia in men receiving ADT.
Bowel Dysfunction
Although acute effects of radiation on the rectal wall causing
bowel irregularity, excessive flatulence, cramps, and diarrhea
are common, late effects are increasingly less common due to
improved planning and delivery techniques. Rectal bleeding,
particularly for patients taking aspirin or anticoagulants, may
be due to thinning and telangiectasia of the rectal mucosa.
Acute effects may respond to stool softeners (ie, psyllium or
methylcellulose powder or docusate), topical steroids, or
antiinflammatories (ie, hydrocortisone suppositories, mesal-
amine, or hydrocortisone enemas).99,100 Persistent and sub-
stantial bleeding might require careful evaluation by a
gastroenterologist or colorectal surgeon with appropriate
expertise and experience. Rectal ulceration potentially lead-
ing to rectourethral fistula is a risk, particularly if tissues are
traumatized and deep biopsies with cauterization of telan-
giectatic tissues are performed. Other late effects might
include anal sphincter dysfunction, rectal urgency, pain, and
frequency. These may be improved with dietary consulta-
tion, referral to the radiation oncologist for management
suggestions, hyperbaric oxygen therapy,101 and the involve-
ment of an experienced gastrointestinal specialist.99
Cardiovascular and Metabolic Effects
Primary care clinicians should be aware that troubling
effects of ADT on cardiovascular and diabetic disease have
been reported in prostate cancer survivors,102 but evidence
of heightened risk as a result of prostate cancer treatment
remains unclear. In a systematic review, men treated with
ADT had a 17% increase in cardiovascular-related mortal-
ity compared with men who did not undergo ADT.103
While some trials show nonstatistically significant increases
in cardiovascular mortality for men receiving ADT,104-106
others have demonstrated that even short-term ADT use is
associated with a shortened time to fatal myocardial infarc-
tion in men aged 65 years or older.107,108 However, a meta-
TABLE 5. Guidelines for Screening and Early Detection of Second Primary Cancers
GUIDELINE LEVEL OF EVIDENCEa
Adhere to American Cancer Society screening and early detection guidelines (cancer.org/professionals).
Prostate cancer survivors having undergone radiation therapy may have slightly higher risk of bladder
and colorectal cancers and may need to follow screening guidelines for higher-risk individuals, if available.
I
For survivors presenting with hematuria, perform a thorough evaluation to rule out bladder cancer,
including urologist referral for cystoscopy.
IIC
Refer survivors presenting with persistent rectal bleeding, pain, or other symptoms of unknown origin to the
appropriate specialist as well as the treating radiation oncologist to conduct a thorough evaluation for rectal cancer.
0
aLevel of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of prostate cancer survivors; IB, RCT based on cancer survivors across
multiple sites; IC, RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (eg, managing urinary
incontinence, erectile dysfunction, etc); IIA, non-RCT based on prostate cancer survivors; IIB, non-RCT based on cancer survivors across multiple sites;
IIC, non-RCT not based on cancer survivors, but on general population experiencing a specific long-term or late effect (eg, managing urinary incontinence,
erectile dysfunction, etc); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study.
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analysis pooling 4141 patients with a variety of nonmeta-
static and non–hormone-refractory disease from 8 random-
ized trials revealed that cardiovascular death in men
receiving ADT versus control was not significantly different
among patients with prostate cancer.109
Metabolic syndrome has also been associated with ADT.
Androgen deprivation may result in obesity, a decline in
lean mass, decreased insulin sensitivity, increased high-
density lipoprotein levels, and subcutaneous rather than vis-
ceral fat accumulation.107 Attempts at defining specific
FIGURE 2. Sexual Health Inventory for Men. An abridged 5-item version of the 15-item International Index of Erectile Function (IIEF-5) was developed
to diagnose the presence and severity of erectile dysfunction (ED). Because of its simplicity and the favorable diagnostic properties reported herein, the
IIEF-5 could aid in decreasing incorrect diagnoses of ED and decreasing the number of undiagnosed cases of ED worldwide. Reprinted with permission
from Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pe~na BM. Development and evaluation of an abridged, 5-item version of the International Index of
Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319-326.93 Copyright VC 1999 Pfizer, Inc. All rights
reserved. Available at: pfizerpatientreportedoutcomes.com.
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TABLE 6. Guidelines for Assessment and Management of Physical and Psychosocial Long-Term and Late Effects
GUIDELINE LEVEL OF EVIDENCEa
Anemia: specific risk for men receiving ADT
l Perform annual CBC to monitor hemoglobin levels.
0
Bowel dysfunction
l Discuss bowel function and symptoms (eg, rectal bleeding) with survivors.
l For men with a negative colorectal cancer screening result, prescribe stool softeners, topical steroids,
or antiinflammatories for survivors experiencing rectal bleeding.
l Refer survivors with persistent rectal symptoms (eg, bleeding, sphincter dysfunction, rectal urgency
and frequency) to the appropriate specialist.
0
Cardiovascular and metabolic effects: specific risk for men receiving ADT
l Follow USPSTF guidelines for evaluation and screening for cardiovascular risk factors, blood pressure monitoring,
lipid profiles, and serum glucose (uspreventiveservicestaskforce.org/uspstopics.htm).
A: hypertensionb
B, I: type II diabetesb
A, B: lipid disordersb
Distress/depression/PSA anxiety
l Assess for distress/depression/PSA anxiety periodically (at least annually) using a simple screening tool,
such as the Distress Thermometer.
l Manage distress/depression using in-office counseling resources or pharmacotherapy as appropriate.
l If office-based counseling and treatment are insufficient, refer survivors experiencing distress/depression for
further evaluation and or treatment by appropriate specialists.
0
Fracture risk/osteoporosis: specific risk for men receiving ADT
l Assess risk of fracture for men treated with ADT or older radiation techniques through baseline DEXA scan and
calculation of a FRAX score.
l For men determined to be high risk, prescribe weekly bisphosphonate therapy (oral alendronate at a dose of
70 mg) or annual intravenous zoledronic acid at a dose of 5 mg to increase bone density. Denosumab is also
approved by the FDA to treat men at increased risk of osteoporosis.
2Ac
Sexual dysfunction/body image
l Discuss sexual function with survivors.
l Use validated tools, such as the SHIM, to monitor erectile function over time.
l Erectile dysfunction may be addressed through a variety of options, including penile rehabilitation or
prescription of phosphodiesterase type 5 inhibitors (eg, sildenafil, vardenafil, tadalafil).
l Refer men with persistent sexual dysfunction to a urologist, sexual health specialist, or psychotherapist to
review treatment and counseling options.
0
Sexual intimacy
l Encourage couples to discuss their sexual intimacy and refer to counseling or support services as appropriate.
l Prescribe medication as described above to address erectile dysfunction.
l Instruct couples on use of sexual aids to improve erectile dysfunction for men/male partners as well as
postmenopausal symptoms for women. Refer to mental health professional with expertise in sex therapy.
0
Urinary dysfunction
l Discuss urinary function (eg, urinary stream, difficulty emptying the bladder) and incontinence with all survivors.
l Consider timed voiding, prescribing anticholinergic medications (eg, oxybutynin) to address issues
such as nocturia, frequency, or urgency. Consider alpha-blockers (eg, tamsulosin) for slow stream.
l Refer survivors with postprostatectomy incontinence to a physical therapist for pelvic floor rehabilitation;
at a minimum, instruct survivors about Kegel exercises.
l Refer men with persistent leakage or other urinary symptoms to a urologist for further evaluation
(eg, urodynamic testing, cystoscopy) and discussion of treatment options including surgical placement
of a male urethral sling or artificial urinary sphincter for incontinence.
0
Vasomotor symptoms (eg, hot flushes): specific risk for men receiving ADT
l Although not approved by the FDA for this indication, prescription of selective serotonin or noradrenergic
reuptake inhibitors or gabapentin may offer symptom relief.
0/I (gabapentin trial)
ADT indicates androgen deprivation therapy; CBC, complete blood count; USPSTF, US Preventive Services Task Force; PSA, prostate-specific antigen; DEXA,
dual-energy x-ray absorptiometry; FRAX, World Health Organization Fracture Risk Assessment Tool; FDA, US Food and Drug Administration; SHIM, Sexual
Health Inventory for Men. aLevel of evidence: I, meta-analyses of randomized controlled trials (RCTs); IA, RCT of prostate cancer survivors; IB, RCT based on
cancer survivors across multiple sites; IC, RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (eg,
managing urinary incontinence, erectile dysfunction, etc); IIA, non-RCT based on prostate cancer survivors; IIB, non-RCT based on cancer survivors across mul-
tiple sites; IIC, non-RCT not based on cancer survivors but on general population experiencing a specific long-term or late effect (eg, managing urinary inconti-
nence, erectile dysfunction, etc); III, case study; 0, expert opinion, observation, clinical practice, literature review, or pilot study. bA indicates the USPSTF
recommends the service. There is high certainty that the net benefit is substantial. B indicates that the USPSTF recommends the service. There is high cer-
tainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial. I indicates that the USPSTF concludes
that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the
balance of benefits and harms cannot be determined. cNational Comprehensive Cancer Network rating indicates “Based upon lower-level evidence, there is
uniform consensus that the intervention is appropriate.”
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guidelines that encompass the prevention and treatment of
metabolic syndrome have focused on modifying specific
risk factors through intensive lifestyle modification and
pharmacological therapy.110 Given the variable and contro-
versial evidence regarding the role of ADT in cardiovascu-
lar and diabetic morbidity, no formal recommendations can
be made for any specific cardiac intervention (ie, stress
testing or cardiac catheterization/revascularization). However,
periodic evaluation and screening for cardiovascular risk
factors, blood pressure monitoring, lipid profiles, and serum
glucose should be routine, as provided by joint statement
recommendations from several science advisory panels,111
especially in patients being considered for more than 6 months
of ADT.102,111,112
Distress/Depression/PSA Anxiety
Distress can take the form of myriad unpleasant emotional,
cognitive, and behavioral experiences that, when persistent,
can undermine patients’ coping abilities and negatively
impact HRQOL.113,114 Estimates indicate that as many as
30% of patients with prostate cancer experience clinically rel-
evant general distress,115 25% have increased anxiety, and
nearly 10% experience major depressive disorder.116-118 Most
studies have focused on the year after primary treatment,
with limited evidence suggesting that distress diminishes
within the first 5 years after treatment for some patients.115
Depression is not only a psychological burden for prostate
cancer survivors it also has other associated health consequen-
ces such as medical nonadherence, increased emergency serv-
ice use,116 possible increased rates of suicidal ideation/
suicide,119,120 and declines in urinary and bowel function
after treatment for localized prostate cancer.118,121
Early identification, treatment, and ongoing assessment
for psychological distress are important aspects of survivor-
ship care,122 yet clinicians may inconsistently ask about
psychological distress. A small trial indicated that interven-
tions among prostate cancer survivors who experience psy-
chosocial distress are reported to improve QOL.123
Importantly, African American patients with cancer may be
less likely to seek, to be referred to, and to receive psychoso-
cial services.124,125 Clinical trials show that routine distress
screening and resource referral is effective in relieving distress
over time.126 Survivors should be routinely screened for dis-
tress across all stages of survivorship. In primary care settings,
a simple screening tool (eg, the Distress Thermometer) (Fig.
3)49,127,128 may prove to be most useful in identifying those
patients who require psychosocial care referral or resources.
Some survivors may underreport distress. Consideration
should also be given to partner and family reports of survivor
distress.129 Key risk factors for distress in men that should be
considered include being single/unmarried, having a low
educational level, having advanced disease, having low physi-
cal or cognitive functioning, being of a younger age, having
medical comorbidities, having a psychiatric history, and/or
having poor coping skills.130 Positive screens may warrant
referral for further evaluation and/or treatment if office-
based counseling and treatment are insufficient.131,132
Furthermore, the effects of low testosterone levels may affect
the mood of some men, making them feel depressed or short-
tempered. In one study, men undergoing ADT who had a his-
tory of depression were more likely to develop major depressive
disorder.133,134 For men being considered for ADT, the early
identification of underlying or undertreated depression
through routine screening for depression is recommended.
Illness-related uncertainty is a significant stressor that
negatively impacts HRQOL for some patients.135,136 For
example, PSA surveillance may exacerbate anxiety. PSA
anxiety is common among survivors and symptoms can pres-
ent weeks prior to anticipated testing. Anxiety can interfere
with effective management and result in mistrust of results
or requests for delayed or more frequent testing.137,138 Clini-
cians should be alert to the possibility of PSA anxiety as part
of regular distress screening. Care management and patient
education should aim to reduce uncertainty and perceptions
of unrealistic threat in survivors with elevated testing anxi-
ety. Survivors with significant or persistent PSA anxiety may
be at heightened risk of depressive symptoms or general dis-
tress. Referrals for behavioral intervention may be useful for
symptom reduction and improved tolerance of uncertainty.
Fracture Risk/Osteoporosis
The detrimental effects of ADT on bone metabolism are well
established. Several cohort and cross-sectional studies have
demonstrated accelerated bone loss in men treated with
ADT.110,111,139-141 The loss in bone mineral density is rapid
even during the initial year of treatment, with rates as high as
4.6% in the total hip, femoral neck, and lumbar spine of men
with nonmetastatic prostate cancer.142 In addition, studies
indicate that men treated with ADT had a 2-fold to 5-fold
increased risk of fracture compared with men not treated with
ADT.143-145 Furthermore, one retrospective population-
based study of older radiation techniques demonstrated that
external beam radiation therapy was associated with a 76%
increased risk of hip fracture, which additionally increased to
145% when used in combination with ADT compared with
radical prostatectomy alone.146 Other contributing factors
such as duration of ADT, patient age, and comorbidities may
play a role. More recent conformal radiation techniques have
substantially lessened the risk.
Given the often prolonged natural history of prostate can-
cer in survivors with nonmetastatic, biochemically recurrent
disease,147,148 ADT administration requires close monitoring
for osteoporosis and the development of fractures. In addi-
tion to obtaining a baseline assessment of calcium and
vitamin D levels, counseling regarding adequate dietary
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calcium and vitamin D intake should be instituted and, if
necessary, supplementation should continue during the
course of ADT.40,149 For all men undergoing long-term
ADT, a baseline bone mineral density imaging study (dual-
energy x-ray absorptiometry scan) should be obtained and a
World Health Organization Fracture Risk Assessment Tool
(FRAX) score calculated (available at shef.ac.uk/FRAX/).
Substantial data support that men with a history of osteopo-
rosis or fractures should undergo a dual-energy x-ray absorp-
tiometry scan prior to initiating hormonal therapy as the risk
of fracture increases during the first 6 to 12 months.149-151
ADT should be considered as secondary osteoporosis in the
FRAX algorithm. The NCCN guidelines panel for prostate
cancer recommends bisphosphonate therapy with either
weekly oral alendronate at a dose of 70 mg or annual intrave-
nous zoledronic acid at a dose of 5 mg to increase bone den-
sity in those receiving ADT who are at high risk of fracture
(ie, a 10-year probability of hip fracture is 3% or higher or the
10-year probability of major osteoporosis-related fracture is
20% or higher) as recommended by the National Osteoporo-
sis Foundation.40,149 Denosumab is currently approved by
the US FDA for men undergoing ADT who are at increased
risk of osteoporosis and is recommended as a treatment
option by NCCN.40,110,149,152 Primary care clinicians should
be familiar with the NCCN Task Force Report’s Bone
Health in Cancer Care report149 and the Endocrine Society’s
guidelines for the management of osteoporosis in men.152
Sexual Dysfunction/Body Image
Biological and psychosocial aspects of sexual function are
impacted by prostate cancer treatment. Many men do not
return to their prior level of sexual function after surgery
and there is no standard posttreatment approach to mini-
mize erectile dysfunction (ED).153-157 Older men, those
FIGURE 3. National Comprehensive Cancer Network (NCCN) Distress Thermometer Screening Tool Figure (DIS-A) from the NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines
VR
) for Distress Management (Version 2.2013). Distress, a mix of anxiety and depressive symptoms, may cause
sleeplessness, lack of appetite, trouble concentrating, and difficulty carrying on regular activities. Although some distress is normal, approximately one-
third of patients with cancer experience significant distress. Only approximately 5% of those with cancer obtain psychological help. While distress does
not affect the cancer itself, it does affect how patients cope with their cancer and their ability to follow treatment recommendations. The NCCN Dis-
tress Thermometer measures distress in a similar way to pain, namely, on a scale of 0 to 10, with 10 being the worst. Often, the emotional side effects
of cancer are not discussed in as much detail as the physical side effects. This tool makes it easier for people to talk to their physicians about the emo-
tional effects caused by the diagnosis, symptoms, and treatment of cancer. Patients are encouraged to complete the NCCN Distress Thermometer as
part of their routine appointment preparation. Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
VR
)
for Distress Management (V.2.2013). VC 2013 National Comprehensive Cancer Network, Inc. Available at NCCN.org. Accessed May 22, 2013. To view
the most recent and complete version of the NCCN Guidelines
VR
, go online to NCCN.org.49
CA CANCER J CLIN 2014;64:225–249
VOLUME 64 _ NUMBER 4 _ JULY/AUGUST 2014 239
with preexisting ED, and patients who did not undergo
nerve-sparing surgery are at highest risk of poor erectile
function after surgery. Baseline function and comorbidity
are also important to consider during sexual function recov-
ery.154 Men who experience ED after prostate cancer treat-
ment may have never tried medications or devices to
improve their erections.158 Thus, it is important for primary
care clinicians and primary treating specialists to open the
door to sexual recovery after prostate cancer treatment by
increased awareness and inquiry during routine clinical care.
Although controversial, early penile rehabilitation after
prostate cancer surgery may improve sexual function out-
comes and prevent end-organ penile damage due to neuro-
vascular injury and fibrosis.159-161 For example,
phosphodiesterase type 5 (PDE-5) inhibitors (eg, sildenafil,
vardenafil, and tadalafil) administered early in the course of
recovery may assist with smooth muscle preservation and
improve erectile function through increased tissue oxygen-
ation.162-166 The ability to achieve orgasm is often preserved
after surgery but without ejaculation (ie, anejaculation) and
can even occur without an erection. Urine leakage at orgasm
(ie, climacturia) may also occur (more likely within 1 year
after surgery) and can be mitigated by emptying the bladder
before sexual activity or through the use of condoms.167,168
Penile shortening has also been documented after surgery.169
Although some men may have had a trial period of treat-
ment with a PDE-5 inhibitor, it is usually worth revisiting
because some patients recover erectile function up to 2 to 4
years after surgery.160,161 If unsuccessful or if the patient is
not a candidate due to comorbidity, referral to a urologist or
sexual health specialist is warranted to review treatment
options including an intraurethral dissolvable prostaglandin
pellet, intracavernosal prostaglandin injection, vacuum erec-
tion device,170-172 and penile prosthesis. Combination
therapy may also improve erectile function (eg, sildenafil and
vacuum constriction), although this should be managed in
collaboration with a urologist or sexual health specialist.173
ED is a common long-term effect of radiation ther-
apy.29,38,174 In contrast to the rapid effect of radical prosta-
tectomy on erectile function, which may then improve with
time, ED can be delayed in onset after radiation for a
period of 6 to 36 months.30 This worsening may appear as
a slow decline due to local neurovascular changes, and cer-
tainly have contributing factors such as aging, vascular dis-
ease, diabetes mellitus, and prior pelvic surgery.175 The
percentage of men who experience such erectile issues varies
across studies.154 The use of adjuvant ADT in combination
with radiation therapy will have at least a temporary nega-
tive impact on libido and erectile function.102,176 Similar to
the postsurgical setting, the persistence of bothersome ED
after a trial of PDE-5 inhibitors in appropriate candidates
should prompt referral to a urologist to explore further
medical, surgical, or device treatments.
While limited evidence is available regarding interven-
tions to counteract ED for men receiving ADT, consulta-
tion with a urologist specializing in ED is recommended
for those men who wish to explore possible alternatives.
Although men receiving ADT are deprived of testosterone
and may not experience a strong physiologic desire for sex,
clinical experience suggests that some men wish to continue
sexual activity as an important aspect of their relationship
with a partner. This is based on their psychological desire,
including maintaining intimacy and attending to their part-
ner’s sexual needs.177 Rarely, some men have been able to
attain erections with partner stimulation. If a trial of PDE-
5 inhibitors is not successful, a referral to a urologist is war-
ranted. It is therefore important for clinicians to ask
whether men and their partners wish to address sexuality
and intimacy maintenance while receiving ADT.
Sexual dysfunction is often more complex than solely the
biology of erectile function. Other factors impacting sexual
function include relationship status, depression, anxiety,
grief, mourning, partner sexual dysfunction, and comorbid-
ities.130,178 Should the primary care clinician find the pres-
ence of mitigating psychosocial factors, referral to a sexual
health or psychological professional is warranted.179 More-
over, primary care clinicians and primary treating specialists
should use a brief validated screening tool, such as the Sex-
ual Health Inventory for Men91-93 (Fig. 2) to assess and
monitor erectile function over time. Endpoints beyond
erectile function, such as the quality of erections, consis-
tency of penetrative erections, and erection response with
and without medication assistance should also be elicited
and reported in a standard way across the medical commu-
nity after any prostate cancer treatment. In addition, recog-
nition of the partner’s concerns and relationship aspects of
sexuality are increasingly shown to be vital to sexual recov-
ery.30,180 Primary care clinicians should assess for psycho-
logical distress due to sexual changes and make appropriate
referrals for managing the psychosocial aspects of sexuality.
Survivors may feel supported when they are asked about
their body changes related to prostate cancer treatment, par-
ticularly when the side effects of treatment dominate their
daily lives. Men who do not regain erectile function, who
experience penile shortening, or who experience the demas-
culinizing side effects of hormonal treatment may benefit
from discussing these issues with the primary care clini-
cian.169,181 Men who continue to have bowel or urinary
symptoms may feel regressed and child-like. Men who have
same-sex partners may have many similar concerns, but are
additionally significantly more bothered by the loss of ejacu-
late than heterosexual men; they are thus at a greater risk of
depression or anxiety.182 When affected by treatment side
effects, some men may lose self-regard. A brief exploration
about body image can, if desired, lead to referral to support-
ive counseling for either the survivor or the couple.
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Sexual Intimacy
Patients and partners need support in recovery of their sexual
relationships. All prostate cancer treatments can affect men’s
erectile function.175,183 Men report concern about their erectile
function even when they are recovering well.180,184 Men’s ED
affects partners and couples’ intimate relationships.30,185-188
A partner’s sexual function can also have a significant effect on
erectile function recovery and a partner’s sexual dissatisfaction
can negatively affect a man’s erectile function and satis-
faction.189,190 Additional treatment effects can interfere with
the couple’s recovery of sexual intimacy, such as urinary
incontinence after surgery; bowel and urinary irritation after
radiation; and hot flushes, weight gain, loss of libido, and irrita-
bility due to hormonal deprivation.30,191 Many couples do not
recover their sexual relationship without support.188,192 In such
cases, couples either need help with recovery or with acceptance
of an aspect of the relationship that has been lost. Interventions
to enhance couples’ emotional intimacy and sexual function
have had some success, particularly for couples with fewer psy-
chological resources or lower sexual function.192,193
A multidisciplinary approach is important and effective
for sexual recovery.180,194 Clinicians can prescribe medica-
tion to assist with erectile function. Nurses and clinical sup-
port staff can develop expertise in teaching men to use
medications and mechanical aids to improve erectile func-
tion. For heterosexual couples, nurses can also provide edu-
cation for postmenopausal female partners about methods
to increase lubrication and sexual pleasure. Mental health
professionals trained in sex therapy can help couples
develop a new sexual paradigm based on current function
and willingness to engage in sexual exploration.195,196
Partners should be included in usual prostate cancer survi-
vorship care. They too are often distressed after the prostate
cancer diagnosis and treatment.186,189,197-199 Partners’ and
survivors’ distress are mutually influential.200 Shared decision-
making should include both the patient’s and partner’s needs
during key posttreatment planning of interventions such as
the use of erectile aids, recognition of reactive depression or
anxiety, management of the side effects of ongoing ADT, or
referral to couples’ counseling or sex therapy. Engaging cou-
ples during significant transitions such as biochemical recur-
rence of prostate cancer will provide maximum support and
facilitate mutually acceptable decisions. Life stage and phase
of disease may dictate the kind of support couples need.
Middle-aged couples may be more upset but have more
energy to work on functional recovery, especially in the early
phase of the disease, whereas older couples or those in a later
phase of the disease may experience fatigue and need res-
pite.201 More research is needed to understand and address
the unique needs and concerns of same-sex couples.
Nonpartnered men also require assessment of their sup-
port needs. Treatment side effects can be dispiriting and
without support, men may have difficulty coping or engag-
ing in rehabilitation. If they become isolated, they can
become at risk of prostate cancer-specific mortality.202
Referral to support groups, peer counselors, or supportive
counseling can provide an environment in which single men
can address recovery concerns as well as concerns about find-
ing a partner despite challenges to sexual function.
Urinary Dysfunction
Urinary dysfunction, especially stress incontinence (specifi-
cally termed postprostatectomy incontinence), may be both-
ersome after prostate cancer surgery.28,203,204 Urinary
function and incontinence tend to improve gradually after
surgery and generally remain stable after one year.205-207 The
acute effects of radiation therapy on the urinary tract include
irritative and/or obstructive symptoms presumed secondary
to mucositis and edema (eg, frequency, urgency, hesitancy,
dysuria, and urinary retention). Long-term effects may
include urinary stricture, urinary incontinence, overactive
bladder, fistula, hematuria presumed secondary to telangiec-
tasias or mucosal thinning, decreased bladder capacity, slow-
ing of the urinary stream, nocturia, and urinary retention.28
Unfortunately, many men may be reluctant to initiate a dis-
cussion about incontinence, which means that unless they are
asked for details concerning urinary function, problems will
not be addressed. Due to their interactions with prostate can-
cer survivors for general medical care, primary care clinicians
are well-positioned to ask about urinary continence, the fre-
quency of urination, amount of leakage, and whether pads
are being used. Ideally, the primary treating specialist would
discuss urinary side effect management goals with the patient,
and would provide the primary care clinician with a baseline
patient-reported measure of urinary symptom burden and
management options as well as indications for referral.
Several treatment options exist for urinary symptoms
after prostate cancer surgery. Evidence is inconclusive
regarding the impact of behavioral and pelvic floor physical
therapy referral (eg, Kegel exercises) to improve postprosta-
tectomy stress incontinence, but some men may bene-
fit.208,209 Some men may have urge incontinence or other
irritative urinary symptoms (eg, nocturia, frequency, or
urgency) and might benefit from anticholinergic medica-
tions (eg, oxybutynin) and/or urodynamic testing by a urol-
ogist.210-212 Another long-term and possibly late problem
is slowing of the urinary stream or difficulty emptying the
bladder (ie, elevated postvoid residual urine), possibly due
to urethral stricture or bladder neck contracture.28 Inquir-
ing about changes in the quality and duration of the urinary
stream and incomplete bladder emptying can identify these
potential problems, resulting in an alpha-blocker trial or an
informed referral to a urologist. For men with persistent
leakage, surgical placement of a male urethral sling or artifi-
cial urinary sphincter both greatly reduce and/or eliminate
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urinary incontinence and improve QOL.211,213 Other
incontinence resources include the National Association
For Continence (nafc.org) and the Wound, Ostomy and
Continence Nurses Society (wocn.org).
Comorbidities such as diabetes mellitus may also con-
tribute to urinary dysfunction and lower urinary tract symp-
toms. Hyperbaric oxygen therapy may be of assistance in
conditions in which hypovascularity or hypoxemia contrib-
ute to chronic symptomatology such as in radiation-
induced cystitis. In general, referral to urologists, preferably
those experienced in managing postradiation effects, is war-
ranted for long-term and late urinary complications.28
Vasomotor Symptoms
ADT is associated with a number of adverse physical effects
including vasomotor symptoms (eg, hot flushes), fatigue,
sexual dysfunction, and decreased libido.102,107,110,214 Hot
flushes occur in as many as 40% of men treated with ADT
and may persist for years after treatment.215,216 Although
not approved by the FDA for this indication, treatment
options include the use of selective serotonin reuptake
inhibitors or serotonin-norepinephrine reuptake inhibitors
such as paroxetine at a dose of 10 mg/day or venlafaxine at
a dose of 37.5 mg/day.217 The use of gabapentin is also an
option in treating hot flushes based on randomized clinical
trials in men receiving ADT.102,110,218
CARE COORDINATION AND PRACTICE
IMPLICATIONS
Based on a recommendation from the Institute of Medicine
(IOM), treating specialists should provide survivorship care
plans that include treatment summaries and posttreatment clin-
ical follow-up recommendations to the primary care clinician
to help coordinate this care.3 Primary care clinicians should be
aware that while oncology providers are increasingly providing
survivorship care plans as per the IOM recommendation, new
survivorship care planning accreditation requirements are being
phased in by the American College of Surgeons Commission
on Cancer.219 Primary care clinicians and treating oncology
specialists should confer regarding the survivorship care plan
components and determine roles and responsibilities that are
appropriate for the patient’s condition and the resources avail-
able in the primary care setting. Primary care clinicians should
maintain their role as the general medical care coordinator
throughout the spectrum of prostate cancer detection, treat-
ment, and aftercare, focusing on preventive care and the man-
agement of preexisting comorbid conditions, and regularly
addressing the patient’s overall physical and psychological status
and those components of survivorship care that are mutually
agreed upon with the primary treating specialist (Table 7).
In addition, providing the primary care clinician with a
baseline patient-reported measure of side effect burden offers
a meaningful contribution to the transfer of care. Use of the
EPIC-CP (a one-page clinical tool to measure urinary,
bowel, sexual, and vitality/hormonal health among survivors
of prostate cancer) (Fig. 4)95,220 may be helpful in initiating
the discussion of prostate cancer HRQOL outcomes and
expectations for management, improvement, and referral.
Assessing these long-term and late effects of prostate cancer
and its treatment (eg, urinary, bowel, sexual, and relationship
effects) at least annually is warranted. It is recommended
that primary treating specialists continue to coordinate care
with primary care clinicians to address the long-term physi-
cal and psychosocial effects of prostate cancer, with the
degree of primary care clinician involvement tailored to the
clinician’s level of experience and comfort with survivorship
TABLE 7. Care Coordination Guidelines
GUIDELINE LEVEL OF EVIDENCEa
l The primary treating specialist is encouraged to provide a treatment summary and survivorship care plan to the PCC
when survivorship care is transferred to the PCC. PCCs and treating oncology specialists should confer regarding the
survivorship care plan components and determine roles and responsibilities that are appropriate for the survivor’s
condition and the resources available in the primary care setting.
l PCCs should maintain their role as general medical care coordinator throughout the spectrum of prostate cancer detection,
treatment, and aftercare, focusing on preventive care and the management of preexisting comorbid conditions, regularly
addressing the patient’s overall physical and psychosocial status, and those components of survivorship care that are
mutually agreed upon with the treating clinicians.
l Annually assess for the presence of long-term or late effects of prostate cancer and its treatment. Use of a validated tool
such as EPIC-CP may be helpful in this assessment.
l Encourage the inclusion of caregivers, spouses, or partners in usual prostate cancer survivorship care.
l Refer survivors to appropriate community-based and peer support resources.
0
PCC indicates primary care clinician; EPIC-CP, Expanded Prostate Cancer Index Composite for Clinical Practice. aLevel of evidence: I, meta-analyses of random-
ized controlled trials (RCTs); IA, RCT of prostate cancer survivors; IB, RCT based on cancer survivors across multiple sites, IC, RCT not based on cancer survi-
vors, but on general population experiencing a specific long-term or late effect (eg, managing urinary incontinence, erectile dysfunction, etc); IIA, non-RCT
based on prostate cancer survivors; IIB, non-RCT based on cancer survivors across multiple sites; IIC, non-RCT not based on cancer survivors but on general
population experiencing a specific long-term or late effect (eg, managing urinary incontinence, erectile dysfunction, etc); III, case study; 0, expert opinion,
observation, clinical practice, literature review, or pilot study.
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FIGURE 4. Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP). As survivorship after prostate cancer diagnosis continues to
improve with advances in detection and treatment, the effects of treatment on health-related quality of life are becoming increasingly important. The
changes in quality of life for each prostate cancer treatment modality are well recognized, but the objective characterization and quantification of such
changes are challenging. A validated tool specifically for prostate cancer patients, one that would be practical for use in both community and academic
clinical practices, has not yet been realized. Hence, we set out to develop and validate a relatively brief and accessible quality of life instrument
designed specifically for use in the routine clinical care of prostate cancer patients. This instrument is called EPIC-CP, which stands for Expanded Pros-
tate Cancer Index Composite for Clinical Practice. Reprinted with permission from Chang P, Szymanski KM, Dunn RL, et al. Expanded prostate cancer
index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical
care of patients with prostate cancer. J Urol. 2011;186:865-872.95
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care, and the severity of effects.2,42,95,221 Moreover, discus-
sion of side effect management goals with the survivor may
help inform appropriate referrals to specialists.
Primary care clinicians should manage ongoing care and
detect any new physical and psychosocial effects resulting
from prostate cancer or its treatment. Health promotion and
aggressive management of comorbid conditions should be
routine aspects of care for prostate cancer survivors given their
favorable cancer-specific survival. Primary care clinicians
should continue other ACS-recommended cancer screening
for the early detection of new primary cancers. In addition,
clinicians should capture the patient’s family history to better
understand familial risk factors that might be associated
with second primary cancers and comorbid conditions. The
American Society of Clinical Oncology recommends that, at
a minimum, the following information be obtained on first-
degree and second-degree relatives: type of primary cancer(s),
age at diagnosis, lineage (maternal/paternal), ethnicity, and
results of any cancer genetic testing in any relative.222
LIMITATIONS
Several limitations to these guidelines should be noted. First,
the evidence base in prostate cancer survivorship research is
largely observational and based on small sample sizes with
variability in methodology and measurement of outcomes.
This lack of evidence limits our knowledge of the prevalence
of long-term and late effects among prostate cancer survivors
as well as the best approaches to care. Expert clinical
practice-based opinion and multidisciplinary consensus
drove many of the recommendations. There are opportuni-
ties to improve the knowledge base with respect to many of
the survivorship domains and refine evidence-based care for
prostate cancer survivors. Nonetheless, the recommendations
contained herein and their subsequent implementation are
steps forward for prostate cancer survivors and their clinicians.
Second, the guideline writing process did not include an inde-
pendent systematic evidence review. However, the rigorous lit-
erature reviews, followed by synthesizing evidence with expert
clinical practice-based consensus, have led to an evidence-
based set of recommendations. The guidelines were vetted by
the multidisciplinary expert panel and ACS leadership to
ensure they meet the high standards for ACS endorsement
and to appropriately direct survivorship care. External review
and comment by oncologists, urologists, and primary care
clinicians were conducted prior to submission for publication.
Lastly, guideline development and dissemination in the litera-
ture are only the initial steps in improving the delivery of survi-
vorship care. For this reason, The Survivorship Center
continues to work to make these guidelines and their deriva-
tives easy to use and readily accessible to clinicians during clini-
cal care so that they can more confidently manage the care of
cancer survivors into long-term survival.
SUMMARY
The ACS Prostate Cancer Survivorship Care Guidelines
address health promotion, surveillance for prostate cancer
recurrence, screening for second primary cancers, physical
and psychosocial long-term and late effects assessment and
management, care coordination, and implications for clinical
practice. The guidelines were developed through a systematic
process that included an expert review panel composed of
multidisciplinary experts specializing in the care of patients
with prostate cancer and the treatment of long-term and late
effects experienced by prostate cancer survivors. These guide-
lines are intended to support primary care clinicians caring
for men faced with prostate cancer and its sequelae. The dis-
semination and implementation of these guidelines into clini-
cal practice will be a step forward to improve the delivery of
prostate cancer survivorship care.
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